NewAmsterdam Pharma Company N.V. (NAMS)

22.57 +0.60 (+2.73%) At close: 04:00PM EDT

NewAmsterdam Pharma Company N.V.

Gooimeer 2-35
Naarden 1411 DC
Netherlands
31 35 206 2971
https://www.newamsterdampharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 29

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Michael Harvey Davidson FACC, Facp., M.D.	CEO, President, Executive Board Member & Director	882k	N/A	1956
Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.	Founder, Chief Scientific Officer, Member of Executive Board & Director	677.76k	N/A	1954
Mr. Mayur Amrat Somaiya	Chief Financial Officer	130.58k	N/A	1973
Ms. Juliette Audet M.B.A., M.Sc.	Chief Business Officer	45.62k	N/A	1987
Mr. Douglas F. Kling	Chief Operating Officer	N/A	N/A	1973
Mr. Jim Jacobson	Chief Legal Officer & Secretary	N/A	N/A	N/A
Dr. Marc Ditmarsch M.D.	Chief Development Officer	N/A	N/A	1967
Dr. Sheng Cui Ph.D.	VP & Head of Chemistry Manufacturing and Controls (CMC)	N/A	N/A	N/A
Ms. Annie Neild	VP & Head of Regulatory Affairs	N/A	N/A	N/A
Mr. William Jones Jr., M.B.A.	Chief Commercial Officer	N/A	N/A	1964

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Corporate governance

NewAmsterdam Pharma Company N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.